The world's first combination of two coronavirus vaccines from AstraZeneca and the first component of the domestic drug Sputnik V does not cause serious side effects. This was reported by the Russian Direct Investment Fund (RDIF) with reference to interim results of the study.

Studies safety and immunogenicity of such combination started in February in Azerbaijan, 50 volunteers took part in the vaccination, while enrollment in the clinical trial is still ongoing.

"An interim analysis of the data demonstrates a high safety record for the combination drug: no serious adverse events, and no cases of coronavirus following vaccination," the report said.

The first data on the immunogenicity of the combined vaccine will appear in August.

RDIF was the first in the world to initiate collaboration with other vaccine manufacturers to conduct joint research on the combination of the first component of Sputnik V with foreign drugs.

Made in Russia // Made in Russia

Author: Ksenia Gustova